ACTG ART Interruption Studies: Viral Rebound after Treatment Interruption

These datasets contain data for the N = 235 participants from 6 ACTG studies with Analytic Treatment Interruption (ATI), who were on suppressive antiretroviral treatment (ART), received no immunologic interventions, and had HIV-1 RNA level < 50 copies/mL at time of ATI. As described in the primary paper (Li 2016), the 6 source studies are: ACTG 371, ACTG 5024, ACTG 5068, ACTG 5170, ACTG 5187, ACTG 5197. Note that HIV-1 RNA levels during ATI were measured less frequently in ACTG 5170 (every 4 weeks) than in the other studies. If ACTG 5170 is excluded, the remaining N = 139 participants were in studies where HIV-1 RNA levels were to be measured every 1-2 weeks initially during ATI. N = 124 participants (of the 235) had HIV-persistence data measured prior to ART interruption. These data were examined in Li 2016 and also in multiple statistical methods and modeling papers (Conway 2019, Wang 2020, Lok 2021, Chernofsky 2024, Chernofsky 2025), including causal mediation analysis for the effects of pre-ATI HIV-persistence measures on ATI outcomes. Note that currently conducted ATI studies typically do not include participants taking Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) (see Li et al. 2022), so for use of these data as historical controls for ATI outcomes, recommend exclude those taking NNRTIs at the time of ATI.